LEGAL NOTICES AND DISCLAIMERS
PLEASE READ THIS AGREEMENT CAREFULLY BEFORE ACCESSING THIS WEB SITE. BY ACCESSING THE SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS BELOW. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, YOU MAY NOT ACCESS OR USE THIS SITE.
Duska Therapeutics is working hard to ensure that the information provided on this site is accurate and up-to-date but due to the risk that the information may be compromised by software or procedural errors, Duska Therapeutics does not guarantee the accuracy or completeness of the information provided on this site. Duska Therapeutics reserves the right to make changes to the content of this site from time to time without notice or obligation.
Permission to Browse Site and Limited Permission to Make Copies:
You may browse this site for information and may print copies of its contents for your own use. Written permission is required, however, if you want to incorporate the contents into you own site or written materials, create "derivative works" or revise the site contents. In addition, you may not "mirror" the contents of this site without Duska Therapeutics’ permission. To seek permission, please email info@duskatherapeutics.com
Remember:
Although it may be easy to copy in cyberspace, this does not mean it is legal to do so.
Photo Credits:
SnapVillage, ScientificImages.com and Duska Therapeutics.
Trademarks:
ATPace™, ATPotent™, Vagonixen™, and ATProtect™ are trademarks of Duska Therapeutics Corporation. Registrations exist in the United States and various countries throughout the world. For more complete information regarding the status of a particular trademark in a particular country, please contact Duska Therapeutics.
Copyrights:
Copyright in the pages and in the screens displaying the pages, and in the information and material therein and in their arrangement, are owned by the Duska Therapeutics Corporation unless otherwise indicated.
Links to Third Party Sites:
Please understand that when you access another web site through this one, Duska Therapeutics can accept no responsibility for your experience with the site. In addition, a link to a non-Duska Therapeutics site does not mean that Duska Therapeutics endorses or recommends that site or its contents.
Stock Information:
The information provided under the Investor Information section of this site is provided through a hypertext link to a third party Web site. (See above for important information about links to third party Web sites.) Under no circumstances will Duska Therapeutics be liable for any loss or direct, indirect, incidental, special or consequential damages caused by reliance on this information or for the risks of the stock market.
Communications with Duska Therapeutics:
Any communications or material transmitted to Duska Therapeutics will be treated as non-confidential and non-proprietary. Duska Therapeutics shall be free to reproduce, use, disclose and distribute these communications to third parties without restriction. Duska Therapeutics shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing, and marketing products incorporating such information.
No Warranties; Limitations of Liability:
Duska Therapeutics assumes no responsibility for errors or omissions on this web site. ACCESS TO THIS SITE IS PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. Duska Therapeutics shall not be liable for any special, indirect, incidental, or consequential damages, including without limitation, lost revenues or lost profits, which may result for the use of this site.
Privacy:
Anyone using this server acknowledges that Duska Therapeutics may monitor the server contents as needed to comply with the law, to protect Duska Therapeutics and visitors to this site or server and to ensure that the server is being operated properly.
Located in La Jolla, California, Duska Therapeutics, Inc. develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace(tm), (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website at http://www.duskatherapeutics.com.
Forward-Looking Statement: This release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and certainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of Duska's drug development projects, Duska's limited financial resources and its need to raise additional capital to fund its ongoing working capital and drug development needs, the need for future clinical testing of Duska's drug candidates, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company’s periodic reports on Form 10-KSB and 10-QSB, and any prospectus describing the Company’s securities.
